Trials / Completed
CompletedNCT02549404
Phase 3 Study of KHK7580
Phase 3 Study of KHK7580 (A Long-term Study of KHK7580 in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 137 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This long-term study is designed to evaluate safety and efficacy of KHK7580 orally administered once daily for 52 weeks for patients with secondary hyperparathyroidism receiving hemodialysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KHK7580 | Oral administration |
Timeline
- Start date
- 2015-09-28
- Primary completion
- 2016-12-06
- Completion
- 2016-12-28
- First posted
- 2015-09-15
- Last updated
- 2017-07-05
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02549404. Inclusion in this directory is not an endorsement.